108 related articles for article (PubMed ID: 15781652)
1. Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide.
Marks AJ; Cooper MS; Anderson RJ; Orchard KH; Hale G; North JM; Ganeshaguru K; Steele AJ; Mehta AB; Lowdell MW; Wickremasinghe RG
Cancer Res; 2005 Mar; 65(6):2373-7. PubMed ID: 15781652
[TBL] [Abstract][Full Text] [Related]
2. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
3. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Countouriotis A; Moore TB; Sakamoto KM
Stem Cells; 2002; 20(3):215-29. PubMed ID: 12004080
[TBL] [Abstract][Full Text] [Related]
4. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
5. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody therapy in acute myeloid leukemia.
Feldman EJ
Curr Hematol Rep; 2003 Jan; 2(1):73-7. PubMed ID: 12901157
[TBL] [Abstract][Full Text] [Related]
7. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
Balaian L; Ball ED
Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Balaian L; Ball ED
Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
[TBL] [Abstract][Full Text] [Related]
10. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2004 Oct; 10(20):7043-52. PubMed ID: 15501984
[TBL] [Abstract][Full Text] [Related]
11. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
Bieber MM; Twist CJ; Bhat NM; Teng NN
Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
[TBL] [Abstract][Full Text] [Related]
12. Antibody-targeted horseradish peroxidase associated with indole-3-acetic acid induces apoptosis in vitro in hematological malignancies.
Dalmazzo LF; Santana-Lemos BA; Jácomo RH; Garcia AB; Rego EM; da Fonseca LM; Falcão RP
Leuk Res; 2011 May; 35(5):657-62. PubMed ID: 21168913
[TBL] [Abstract][Full Text] [Related]
13. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.
Vitale C; Romagnani C; Puccetti A; Olive D; Costello R; Chiossone L; Pitto A; Bacigalupo A; Moretta L; Mingari MC
Proc Natl Acad Sci U S A; 2001 May; 98(10):5764-9. PubMed ID: 11320212
[TBL] [Abstract][Full Text] [Related]
14. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
15. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
16. Selective apoptotic killing of solid and hematologic tumor cells by bombesin-targeted delivery of mitochondria-disrupting peptides.
Cai H; Yang H; Xiang B; Li S; Liu S; Wan L; Zhang J; Li Y; Cheng J; Lu X
Mol Pharm; 2010 Apr; 7(2):586-96. PubMed ID: 20141196
[TBL] [Abstract][Full Text] [Related]
17. PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.
Hu C; Xiong J; Zhang L; Huang B; Zhang Q; Li Q; Yang M; Wu Y; Wu Q; Shen Q; Gao Q; Zhang K; Sun Z; Liu J; Jin Y; Tan J
Cell Mol Immunol; 2004 Aug; 1(4):280-94. PubMed ID: 16225771
[TBL] [Abstract][Full Text] [Related]
18. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage.
Hoyer JD; Grogg KL; Hanson CA; Gamez JD; Dogan A
Am J Clin Pathol; 2008 Feb; 129(2):316-23. PubMed ID: 18208813
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation.
Chari RV; Jackel KA; Bourret LA; Derr SM; Tadayoni BM; Mattocks KM; Shah SA; Liu C; Blättler WA; Goldmacher VS
Cancer Res; 1995 Sep; 55(18):4079-84. PubMed ID: 7545085
[TBL] [Abstract][Full Text] [Related]
20. Native antibody and antibody-targeted chemotherapy for acute myeloid leukemia.
Sievers EL
Adv Pharmacol; 2004; 51():169-83. PubMed ID: 15464909
[No Abstract] [Full Text] [Related]
[Next] [New Search]
